Dualyx is developing  unique immune modulators targeting the in vivo expansion of regulatory T cells. Increasing and activating potent Tregs cells can restore the ratio of regulatory to effector T cells and suppress the unwanted autoimmune reaction to achieve long-lasting or even curative treatments in autoimmune disease patients. Through our state-of-art antibody engineering we have developed a pipeline of multi-specific antibodies targeting highly attractive targets. These multi-specific antibodies selectively expand and activate Tregs without activating other immune cells. Dualyx’ innovative antibodies thereby hold the promise of combining effective immune suppression with favorable tox profiles and high therapeutic indices. We are developing our pipeline together with our academic and industry partners such as Wurzburg University, argenx, KU Leuven and VIB.

 

We aim to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity and improved patient outcomes than traditional therapeutics.